Literature DB >> 18456758

Colon cancer: ESMO clinical recommendations for diagnosis, adjuvant treatment and follow-up.

E J D Van Cutsem1, J Oliveira.   

Abstract

Entities:  

Mesh：

Year:  2008        PMID： 18456758     DOI： 10.1093/annonc/mdn077

Source DB:  PubMed          Journal:  Ann Oncol        ISSN： 0923-7534            Impact factor:   32.976


× No keyword cloud information.
  15 in total

1.  Japanese Society for Cancer of the Colon and Rectum (JSCCR) guidelines 2010 for the treatment of colorectal cancer.

Authors:  Toshiaki Watanabe; Michio Itabashi; Yasuhiro Shimada; Shinji Tanaka; Yoshinori Ito; Yoichi Ajioka; Tetsuya Hamaguchi; Ichinosuke Hyodo; Masahiro Igarashi; Hideyuki Ishida; Megumi Ishiguro; Yukihide Kanemitsu; Norihiro Kokudo; Kei Muro; Atsushi Ochiai; Masahiko Oguchi; Yasuo Ohkura; Yutaka Saito; Yoshiharu Sakai; Hideki Ueno; Takayuki Yoshino; Takahiro Fujimori; Nobuo Koinuma; Takayuki Morita; Genichi Nishimura; Yuh Sakata; Keiichi Takahashi; Hiroya Takiuchi; Osamu Tsuruta; Toshiharu Yamaguchi; Masahiro Yoshida; Naohiko Yamaguchi; Kenjiro Kotake; Kenichi Sugihara
Journal:  Int J Clin Oncol       Date:  2011-10-15       Impact factor: 3.402

2.  Surveillance after curative resection of colorectal cancer.

Authors:  Adena Scheer; Rebecca Ann C Auer
Journal:  Clin Colon Rectal Surg       Date:  2009-11

3.  Rectal Cancer Surveillance-Recurrence Patterns and Survival Outcomes from a Cohort Followed up Beyond 10 Years.

Authors:  Winson Jianhong Tan; Hiang Jin Tan; Sreemanee Raaj Dorajoo; Fung Joon Foo; Choong Leong Tang; Min Hoe Chew
Journal:  J Gastrointest Cancer       Date:  2018-12

4.  Inflammation-based Indexes Upon Adjuvant Chemotherapy Initiation as a Predictor of Relapse After Curative Resection of Colorectal Cancer With an Oxaliplatin-based Regimen.

Authors:  Masaya Satake; Kazuhiko Yoshimatsu; Masano Sagawa; Haijime Yokomizo; Shunichi Shiozawa
Journal:  Cancer Diagn Progn       Date:  2022-01-03

5.  An open-label study of the safety and tolerability of pazopanib in combination with FOLFOX6 or CapeOx in patients with colorectal cancer.

Authors:  Joanne Brady; Pippa Corrie; Ian Chau; Raghunadharao Digumarti; Laurel M Adams; Jeffrey Botbyl; Kevin H Laubscher; Rachel S Midgley; Mohandas Mallath
Journal:  Invest New Drugs       Date:  2013-02-28       Impact factor: 3.850

6.  The lymph node ratio is a powerful prognostic factor of node-positive colon cancers undergoing potentially curative surgery.

Authors:  Gennaro Galizia; Michele Orditura; Francesca Ferraraccio; Paolo Castellano; Margherita Pinto; Anna Zamboli; Sabrina Cecere; Ferdinando De Vita; Carlo Pignatelli; Eva Lieto
Journal:  World J Surg       Date:  2009-12       Impact factor: 3.352

7.  Feasibility study of S-1 adjuvant chemotherapy in patients with colorectal cancer.

Authors:  Masaichi Ogawa; Michiaki Watanabe; Tetsuya Kobayashi; Ken Eto; Akihiro Oda; Tadashi Anan; Takenori Hayashi; Yoshinobu Mitsuyama; Katsuhiko Yanaga
Journal:  Int J Clin Oncol       Date:  2012-05-15       Impact factor: 3.402

8.  Predictive value of orotate phosphoribosyltransferase in colorectal cancer patients receiving 5-FU-based chemotherapy.

Authors:  Shuji Komori; Shinji Osada; Hiroyuki Tomita; Kimitoshi Nishio; Iwao Kumazawa; Susumu Tachibana; Juji Tsuchiya; Kazuhiro Yoshida
Journal:  Mol Clin Oncol       Date:  2013-01-17

9.  Study protocol of the SACURA trial: a randomized phase III trial of efficacy and safety of UFT as adjuvant chemotherapy for stage II colon cancer.

Authors:  Megumi Ishiguro; Hidetaka Mochizuki; Naohiro Tomita; Yasuhiro Shimada; Keiichi Takahashi; Kenjiro Kotake; Masahiko Watanabe; Yukihide Kanemitsu; Hideki Ueno; Toshiaki Ishikawa; Hiroyuki Uetake; Shigeyuki Matsui; Satoshi Teramukai; Kenichi Sugihara
Journal:  BMC Cancer       Date:  2012-07-07       Impact factor: 4.430

10.  Clinical Significance of Lymph Node Ratio in Stage III Colorectal Cancer.

Authors:  Yo Han Park; Jae Im Lee; Jong Kyung Park; Hang Ju Jo; Won Kyung Kang; Chang Hyeok An
Journal:  J Korean Soc Coloproctol       Date:  2011-10-31
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.